WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002006274) N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/006274    International Application No.:    PCT/US2001/022379
Publication Date: 24.01.2002 International Filing Date: 16.07.2001
Chapter 2 Demand Filed:    01.02.2002    
IPC:
C07D 211/58 (2006.01), C07D 401/12 (2006.01), C07D 401/14 (2006.01), C07D 417/14 (2006.01)
Applicants: WYETH [US/US]; Five Giralda Farms Madison, NJ 07940-0874 (US)
Inventors: SUM, Fuk-Wah; (US).
MALAMAS, Michael, Sotirios; (US)
Agent: ECK, Steven, R.; Wyeth Patent Law Department Five Giralda Farms Madison, NJ 07940 (US).
WILEMAN, David Francis; CONNELLY, Michael John; MANNION, Sally Kim; and TALBOTT, Dawn Jaqueline; c/o Wyeth Laboratories Huntercombe Lane South Taplow Maidenhead Berkshire SL6 0PH, GB (GB)
Priority Data:
60/218,589 17.07.2000 US
Title (EN) N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS
(FR) N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES: AGONISTES DU RECEPTEUR BETA-3 ADRENERGIQUE
Abstract: front page image
(EN)The invention provides compounds of Formula I having the structure (I), wherein R¿1?, R¿2?, R¿3?, R¿4?, W, X, and Y are as defined hereinbefore or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.
(FR)L'invention concerne des composés représentés par la formule (I) dans laquelle R¿1?, R¿2?, R¿3?, R¿4?, W, X, et Y sont tels que définis dans la description, ainsi que des sels pharmaceutiquement acceptables de ces composés. Ces produits sont utilisés pour traiter ou inhiber des troubles métaboliques associés à la résistance à l'insuline ou à l'hyperglycémie.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)